463 related articles for article (PubMed ID: 27029056)
21. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
[TBL] [Abstract][Full Text] [Related]
22. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
24. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B; Thomare P; Delande E; Moynard J; Gastinne T; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Boudreault JS; Perrin F; Lok A; Guillaume T; Garnier A; Peterlin P; Gallas P; Chevallier P; Moreau P; Le Gouill S
Ann Hematol; 2017 Jun; 96(6):943-950. PubMed ID: 28374163
[TBL] [Abstract][Full Text] [Related]
25. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma.
Bessell EM; Graus F; López-Guillermo A; Villá S; Verger E; Petit J; Holland I; Byrne P
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):457-64. PubMed ID: 11380234
[TBL] [Abstract][Full Text] [Related]
26. Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.
Atilla PA; Atilla E; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Demirer T; Ilhan O; Arslan O; Gurman G; Ozcan M
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):13-17. PubMed ID: 28633037
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Korfel A; Thiel E
Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
[TBL] [Abstract][Full Text] [Related]
28. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
29. Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.
Wu J; Duan L; Zhang L; Sun Z; Fu X; Li X; Li L; Wang X; Zhang X; Li Z; Yu H; Chang Y; Nan F; Yan J; Tian L; Wang X; Zhang M
J Neurooncol; 2018 Nov; 140(2):427-434. PubMed ID: 30109672
[TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
[TBL] [Abstract][Full Text] [Related]
31. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
[TBL] [Abstract][Full Text] [Related]
32. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma.
Zhao HT; Chen J; Shi SB; Tian J; Tao RJ
Med Oncol; 2015 Jan; 32(1):351. PubMed ID: 25428379
[TBL] [Abstract][Full Text] [Related]
34. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Abdayem P; Ibrahim N; El Dakdouki Y; Willekens C; Ghez D; A Rouche J; Dartigues P; Desmaris R; Danu A; Rossignol J; Lazarovici J; Fermé C; Ribrag V; Michot JM
Eur J Haematol; 2021 Apr; 106(4):574-583. PubMed ID: 33512026
[TBL] [Abstract][Full Text] [Related]
35. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Schorb E; Fox CP; Kasenda B; Linton K; Martinez-Calle N; Calimeri T; Ninkovic S; Eyre TA; Cummin T; Smith J; Yallop D; De Marco B; Krampera M; Trefz S; Orsucci L; Fabbri A; Illerhaus G; Cwynarski K; Ferreri AJM
Br J Haematol; 2020 Jun; 189(5):879-887. PubMed ID: 31997308
[TBL] [Abstract][Full Text] [Related]
36. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
37. Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series.
Chamberlain MC
J Neurooncol; 2013 May; 113(1):27-32. PubMed ID: 23456654
[TBL] [Abstract][Full Text] [Related]
38. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Laack NN; O'Neill BP; Ballman KV; O'Fallon JR; Carrero XW; Kurtin PJ; Scheithauer BW; Brown PD; Habermann TM; Colgan JP; Gilbert MR; Hawkins RB; Morton RF; Windschitl HE; Fitch TR; Pajon ER;
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):476-82. PubMed ID: 20800387
[TBL] [Abstract][Full Text] [Related]
39. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma.
Mason JO; Fischer DH
Ophthalmology; 2003 Jun; 110(6):1241-4. PubMed ID: 12799254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
